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CYCLOSPORINE is an  effective drug  in  acute  exacerba-
tions of corticosteroid resistant ulcerative colitis, but
its efficacy to maintain disease remission is not clear.
Cyclosporine  may  not  be  as  effective  in  Crohn’s
disease. However, being a rapidly acting immunosup-
pressant, cyclosporine may be a valuable therapeutic
option in the short-term to treat corticosteroid resist-
ant Crohn’s disease and ulcerative colitis.
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Introduction
The  efficacy of  immunosuppressive  drugs  like  aza-
thioprine and 6-mercaptopurine to treat the chronic
inflammatory bowel diseases (IBD) ulcerative colitis
(UC)  and  Crohn’s  disease  (CD)  is  now  generally
accepted. However, a major drawback to the use of
these immunosuppressants is the 2–3 month delay in
onset of their clinical action, thereby limiting their
role in severe acutely active disease.
The  success  of  the  rapidly  acting  immunosup-
pressive  drug  cyclosporine  in  solid  organ  trans-
plantation  and  chronic  inflammatory  diseases  such
as psoriasis and rheumatoid arthritis paved the way
to  determine  the  efficacy  of  cyclosporine  in  IBD.
The following review will focus on clinical response
in  controlled  trials,  pharmacology,  side  effects  and
toxicity of cyclosporine treatment in CD and UC.
Cyclosporine in Crohn’s Disease
Numerous  open  studies  have  suggested that  cyclo-
sporine may be effective in active CD which has not
responded to conventional treatment including cor-
ticosteroids, aminosalicylates and antibiotics.1 How-
ever, only four controlled trials of cyclosporine for
the  treatment  of  CD  have  been  published.2–6 In
three of these studies a total number of 633 patients
was treated with low-dose oral cyclosporine (5mg/
kg/day  and  whole  blood  concentrations  ranging
from  100–250ng/ml)  or  placebo.4–6 These  studies
failed  to  demonstrate  any  significant  beneficial
effect  of  chronic  low-dose  oral  cyclosporine  for
chronically active CD or for remission maintenance.
Given  alone  as  initial  treatment,  cyclosporine  was
less effective than conventional treatment.7
Only  one  controlled  study  using  high-dose  oral
cyclosporine  (5–7.5mg/kg/day)  for  CD  has  been
published.2,3 At 3 months 59% of the patients treated
with cyclosporine had improved compared with 32%
in the placebo group.2 The whole blood concentra-
tions were higher in the responders (471ng/ml) than
in  the  nonresponders  (309ng/ml).  However,  the
beneficial effect did not persist after cyclosporine was
stopped.3 Two  studies  have  suggested  efficacy  of
cyclosporine for fistulizing CD.8,9 At present, it seems
reasonable to limit the use of cyclosporine to patients
with  severely  active  CD  who  failed  to  respond to
corticosteroids and aminosalicylates, and preferably
in a clinical research setting.
Cyclosporine in Ulcerative Colitis
Several open studies have reported a beneficial effect
of cyclosporine in the treatment of UC.10,11 Only one
small controlled trial showed that cyclosporine, given
in an intravenous dosage of 4mg/kg/day comparable
with an oral dosage of 12–16mg/kg/day, will induce a
remission in 83% of patients with severe ulcerative
colitis  compared  with  0%   of  the  placebo-treated
patients.12 It is important to realize that only 45% of
these patients avoided colectomy during 6 months of
follow-up.13 One controlled trial of low-dose cyclo-
sporine  enemas  for  left-sided  UC  had  negative
results.14
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that  50–70%  of  the  patients  will  require  surgery
during the following 12 months after starting cyclo-
sporine therapy. However, using cyclosporine treat-
ment  some  patients,  especially  those  with  a  first
attack, will not lose their colon. In others, colectomy
can  be  performed  when  the  patient  is  in a  better
physical condition and the ileo-anal pouch anastomo-
sis done as a one-stage procedure without the need of
a  stoma.  Recently,  an  excellent  paper  has  been
published describing in detail guidelines how to use
and  monitor  cyclosporine  treatment  in  UC
patients.15
Pharmacology
Cyclosporine  is a lipophilic peptide  which  inhibits
T -helper cell interleukin-2 (IL-2) mRNA transcription
and production, and also the release of other lympho-
kines such as interferon-gamma, IL-3, IL-4, IL-5, and
tumour  necrosis  factor-alpha,  resulting  in altered T
cell  and  B  cell  function.16,17 At  present,  it  is  not
known whether these effects on cellular and humoral
immunity account for any therapeutic effect in IBD.
Alternatively, neutralization of the neutrophil chem-
otactic  properties  of  extracellular  cyclophillin  by
cyclosporine has been proposed as the primary mode
of action in IBD.18 This hypothesis could explain the
better  responsiveness  to  cyclosporine  in  UC  com-
pared with CD, because in UC neutrophil influx may
play a bigger role than in CD. Although the effective-
ness of cyclosporine in treating IBD could be dose
related, there  is also evidence  that  low-dose cyclo-
sporine  may  even  worsen  tissue  inflammation  and
injury  by changing  specific  lymphocyte subpopula-
tions.18 In  mice,  it  has  been  shown  that  low-dose
cyclosporine causes a switch from a T -helper 1 to a
T -helper 2 response thereby augmenting the inflam-
matory response.19
The distribution and elimination kinetics of cyclo-
sporine in patients with CD do not differ from those
in  other  patient  groups  or  controls,  whereas  the
extent  and  rate  of  oral  bioavailability  may  be
decreased.20,21The absorption of cyclosporine can be
described by zero-order kinetics in patients with CD,
implying that the gut transit time is important for the
amount of cyclosporine absorbed.20 In one study, 10%
of patients with CD showed cyclosporine malabsorp-
tion based on blood levels.4 In addition, absorption of
cyclosporine  is  significantly  affected  by  bile  salts.
Recently, a new formulation of cyclosporine–Neoral–
has  been  developed,  which  consists  of  a  micro-
emulsion of cyclosporine employing a surfactant,  a
lipophilic solvent, a hydrophilic solvent, and a cosol-
vent.22 This new formulation ensures rapid release of
cyclosporine within  the gastrointestinal  tract and a
more uniform presentation to the absorptive surface
of the upper small bowel. This results in consistent
dispersion  of  the  drug  in  the  gastrointestinal  tract
without the need for additional emulsifiers like bile
salts. Studies have demonstrated that in patients with
CD  who  have  problems  absorbing  cyclosporine,
conversion to Neoral results in correction of cyclo-
sporine  malabsorption.22 At  present,  however,  it
remains  unclear  whether  initial  therapy with  intra-
venous  cyclosporine  is  superior  to  oral
administration.
Side Effects and Toxicity
Being a powerful immunosuppressant, cyclosporine
also has potential side effects including: renal insuffi-
ciency (6% ), hypertension (11%), infectious complica-
tions  (3% ),  severe  neurological  disorders  including
epilepsy (1%),  paresthesias (26–70%),  tremor  (7% ),
headache (5% ), hypertrichosis (13% ), gingival hyper-
plasia (2% ), and anaphylaxis (0.3%)23–26 (Table 1).
Cyclosporine is metabolized in the liver and both
cyclosporine and its metabolites are excreted in bile
and  little  cyclosporine  appears  in the  urine.  Renal
impairment does not alter the elimination of cyclo-
sporine. Any drug that inhibits the cytochrome P-450
system  will  increase  cyclosporine  levels  (ketocona-
zole,  fluconazole,  cimetidine,  erythromycin,  diltia-
zem, verapamil), whereas drugs that induce the P-450
system will decrease cyclosporine levels (rifampicin,
phenobarbital, phenytoin, carbamazepine).
Nephropathy due to long-term cyclosporine treat-
ment  is  an  important  issue.  The  direct  effect  of
cyclosporine is a vasoconstriction of preglomerular
arterioles  with  a  secondary decrease  in glomerular
filtration  rate  and  an  increased  proximal  tubular
fractional  reabsorption  rate.  This  may  result  in
increased tubular transit time and tubular atrophy and
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Table 1. Side effects of cyclosporine
Side effects which tend to occur during chronic
administration
d hypertrichosis
d gingival hyperplasia
d hypomagnesaemia
d gout
d diabetes mellitus
Side effects requiring dose reduction
d hypertension
d paresthesias
d tremor
d headache
d increase in serum creatinine > 30%
Side effects requiring stopping cyclosporine administration
d jaundice
d infectious complications (especially Pneumocystis carinii
and fungal infections)
d lymphoma
d anaphylaxis
d severe neurological disorders including epilepsyinterstitial fibrosis.20 It has been suggested that one-
fifth  of  patients  with  autoimmune  diseases  treated
with  cyclosporine  have  histological  evidence  of
nephropathy.27
A  few  case  reports  dealing  with  severe  and
sometimes  fatal  opportunistic  infections have  been
reported.23–26 Importantly, these infections occurred
during high-dose cyclosporine treatment in combina-
tion with corticosteroids.
Conclusions
Cyclosporine  is  an  effective  therapeutic  option  in
acute exacerbations of UC not responding to corticos-
teroids. When  given  orally, its  long-term  efficacy  is
questionable. Low-dose oral cyclosporine is not effec-
tive in either quiescent or active CD. Cyclosporine
can  be  used as rescue  therapy  to ‘buy  time’:  most
patients who benefit on the short-term from cyclo-
sporine, will require further treatment for their IBD in
the  form  of  follow-up  surgery  or  other  remission
maintaining drugs like azathioprine or 6-mercaptopur-
ine.  The  introduction  of  a  new  formulation  of
cyclosporine has improved the absorption kinetics of
the drug and the consistency of plasma levels after
oral  dosage.  Cyclosporine  side  effects,  especially
nephrotoxicity, are common necessitating  adequate
monitoring.
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